Core Global Portfolio Drives Takeda Despite Pockets Of Weakness
Entyvio Solid But Hematology More Challenging
Japanese firm raises full-year forecast for core operating profit on continued growth for global brands, despite US recall and hematology pressures.
You may also be interested in...
In a continued effort to pay down its debt pile from the acquisition of Shire, Takeda is to offload around 30 selected OTC and Rx products in certain Middle East and other emerging markets to private Swiss group Acino.
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.